New insider activity at Medtronic ( (MDT) ) has taken place on November 21, 2025.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Gregory L. Smith, the Executive Vice President of Global Operations & Supply Chain at Medtronic, recently sold 5,814 shares of the company’s stock. This transaction was valued at $593,172.
Recent Updates on MDT stock
Medtronic has reported strong Q2 financial results, with a 6.6% increase in revenue to $9 billion and an 8% rise in GAAP diluted EPS to $1.07. The growth was driven by significant increases in Cardiac Ablation Solutions and Cardiovascular Portfolio revenues, alongside FDA approvals and favorable coverage for new products. The company raised its fiscal year 2026 guidance, projecting 5.5% organic revenue growth and higher EPS, supported by strategic investments in R&D and marketing. Analysts have raised price targets, citing new product momentum, improved P&L metrics, and accelerated growth in R&D and SG&A. Despite challenges like declining cryo revenue and tariff impacts, Medtronic’s innovative product launches and strategic initiatives are expected to sustain future growth.
Spark’s Take on MDT Stock
According to Spark, TipRanks’ AI Analyst, MDT is a Outperform.
Medtronic’s strong financial performance and positive earnings call outlook are the most significant factors driving the score. Technical indicators support a bullish trend, though valuation concerns slightly temper the outlook. Overall, the company is well-positioned for growth despite some challenges.
To see Spark’s full report on MDT stock, click here.
More about Medtronic
YTD Price Performance: 27.36%
Average Trading Volume: 6,954,834
Technical Sentiment Signal: Buy
Current Market Cap: $128.7B